Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Dose-Response Effects of a 6-Week Progressive Resistance Training Program on Premenstrual Syndrome in Adolescent Girls

10. august 2026 opdateret af: Riphah International University
This study examines the dose-response effects of a 6-week progressive resistance training program on premenstrual syndrome (PMS) in adolescent girls. PMS is a common condition that affects physical, psychological, and social well-being. While exercise is known to reduce symptoms, the optimal intensity of resistance training remains unclear. Using a randomized controlled trial design, participants are assigned to progressive or low-intensity training groups. PMS symptoms and quality of life are assessed over time. The study aims to determine whether higher exercise intensity leads to greater symptom reduction and improved overall well-being.

Studieoversigt

Detaljeret beskrivelse

This study focuses on premenstrual syndrome (PMS), a common cyclical condition experienced by adolescent girls that includes physical, psychological, and behavioral symptoms such as pain, mood swings, anxiety, fatigue, and reduced concentration. These symptoms can negatively affect academic performance, social interactions, and overall quality of life. Exercise has been shown to improve hormonal balance, reduce stress, and enhance mood through the release of endorphins and serotonin. However, most existing research has focused on aerobic exercise, with limited attention given to resistance training. Resistance training, which involves strengthening muscles through weights or bodyweight exercises, may offer additional benefits, but its optimal intensity and effectiveness for PMS management remain unclear. This study addresses this gap by examining the dose-response relationship of resistance training.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

32

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Federal
      • Islamabad, Federal, Pakistan, 051
        • Rekruttering
        • Kens college model town humak and community model town
        • Kontakt:
      • Islamabad, Federal, Pakistan, 051
        • Rekruttering
        • Kid city high school
        • Kontakt:
        • Ledende efterforsker:
          • Amina Rizwan, MSPT(WH)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Diagnosed with Premenstrual Syndrome (PMS) based on PSST screening tool.
  2. Not currently engaged in any structured resistance or exercise training program.
  3. Medically cleared to participate in moderate-intensity resistance training.
  4. Provided written informed consent for participation.

Exclusion Criteria:

  1. Current use of hormonal therapy or oral contraceptives.
  2. History of endocrine disorders (e.g., PCOS, thyroid dysfunction).
  3. Any musculoskeletal or cardiovascular condition limiting exercise participation.
  4. Ongoing psychiatric medication or diagnosed depression/anxiety disorder.
  5. Participation in a structured exercise or resistance training program within the last 3 months.
  6. Use of analgesics, anti-inflammatory, or hormonal medications during the study period.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Progressive Resistance Training Group
Participants allocated to this arm will receive a supervised 6-week progressive resistance training program performed three times per week on non-consecutive days. Each session will last 45-60 minutes.

A supervised progressive resistance training program delivered three sessions per week for six weeks. Exercise intensity is gradually increased using the Borg Rating of Perceived Exertion (RPE) scale.

A warm up session will be done before resistance training exercise and Cool down for 5-10 minutes will be done exercise.

Participants will follow the FITT prescription for their resistance exercises.

Week 1-2 (DOSE 1) Intensity: Low. Bodyweight or dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 25-30 reps. Volume: High. Focus on mastering technique. Week 3-4 (DOSE 2) Intensity: moderate. Bodyweight or dumbbells (RPE 12-14/20). Sets & Reps: 2 sets of 20-25 repetitions. Volume: Moderate. Focus on mastering technique. Week 5-6(DOSE 3) Intensity: high. Dumbbells (RPE 15-16/20). Sets & Reps: 2 sets of 15-20 repetitions. Volume: Low.

Aktiv komparator: Low-Intensity Resistance Training Group
Participants allocated to this arm will receive a supervised low-intensity resistance training program for six weeks. Sessions will be conducted three times per week, lasting 45-60 minutes each. Participants will perform the same standardized resistance exercises as the experimental group; however, exercise intensity will remain low throughout the intervention without progressive overload.

Participants of this group will receive the same standardized exercises as the experimental group. Exercise intensity remains constant at low intensity throughout the intervention period without progressive increase.

Before exercise the participants will perform warm up and after exercise they will perform cool down, same as the experimental group.

The FITT protocol for this group is as following:

Week 1-2 (DOSE1) Intensity: low Body weight. or Dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 15repetitions. Volume: Low. Focus on mastering technique. Week 3-4 (DOSE 2) Intensity: low. Bodyweight or dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 20 repetitions. Volume: Moderate. Focus on mastering technique Week 5-6(DOSE 3) Intensity: Low. Bodyweight or dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 25 reps. Volume: High. Focus on mastering technique.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Premenstrual Symptoms Screening Tool (PSST)
Tidsramme: Assessments will be conducted at baseline, week 2, week 4, week 6, and at 3-month follow-up
The primary outcome of this study is the severity of premenstrual syndrome symptoms, measured using the Premenstrual Symptoms Screening Tool (PSST). The PSST is a self-reported questionnaire used to assess physical, psychological, and behavioral symptoms related to PMS, including mood swings, irritability, anxiety, fatigue, bloating, breast tenderness, and difficulty concentrating. It also evaluates how these symptoms affect daily activities, school performance, and social relationships. Each item is scored on a 4-point Likert scale ranging from "none" to "severe." Higher scores indicate greater PMS severity..
Assessments will be conducted at baseline, week 2, week 4, week 6, and at 3-month follow-up

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Quality of Life (QoL)
Tidsramme: Quality of life will be assessed at baseline, immediately after the 6-week intervention, and at 3-month follow-up using the WHOQOL-BREF questionnaire.
Quality of life will be assessed using the World Health Organization Quality of Life Questionnaire (WHOQOL-BREF). This questionnaire contains 26 items and evaluates four domains: physical health, psychological health, social relationships, and environmental well-being. Each item is rated on a 5-point Likert scale, with higher scores representing better quality of life. The WHOQOL-BREF is a reliable and valid tool commonly used in clinical and research settings to assess overall well-being.
Quality of life will be assessed at baseline, immediately after the 6-week intervention, and at 3-month follow-up using the WHOQOL-BREF questionnaire.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Rida Zafar, WHPT, Riphah International University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. august 2026

Primær færdiggørelse (Anslået)

1. november 2026

Studieafslutning (Anslået)

1. januar 2027

Datoer for studieregistrering

Først indsendt

5. august 2026

Først indsendt, der opfyldte QC-kriterier

5. august 2026

Først opslået (Faktiske)

10. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

IPD will not be shared to ensure participant confidentiality and data protection, particularly because the study involves adolescent girls, and data was collected for specific research purposes only."

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner